Microfluidic devices are considered versatile tools in the field of disease therapy research. For therapeutic drug discovery, microfluidic technologies are employed to produce lead compounds with controlled physicochemical properties, to characterize them in a high-throughput fashion, and evaluate them in human organ-on-a-chips. Also, they are applied for the development and production of vaccines as well as screening and production of target delivery carriers such as nanoparticles.
Creative Biolabs is a pioneer in the field of microfluidic research and application. Leveraging our experience and expertise, we support a full range of top-quality microfluidic-based services tailored to meet your R&D timeline and budget. We aim to speed up the process of drug and vaccine development and promote your success.
Organ-on-a-chip is an advanced microfluidic technology that can recapitulate the multicellular architectures, tissue-tissue interfaces, physicochemical microenvironments and vascular perfusion of the body and provide an excellent model for drug discovery and development. Organ-on-a-chip is more reflective of the physical and biochemical characteristics of the body compared to conventional cell culture models and cheaper and easier to operate and control compared to animal models. One limitation of the in vivo model is that it is difficult to accurately monitor and control the microenvironment in living organisms, while organ-on-a-chip allows high-resolution, real-time imaging and in vitro analysis of biochemical, genetic and metabolic activities of living cells in a functional organ context.
Now the different types of organs on chips have been developed such as lung, liver, heart, and brain. Interestingly, most disease models such as tumor and neurodegenerative diseases were also developed on a chip, which is valuable for the study of molecular mechanisms of action, prioritization of lead candidates, toxicity testing and biomarker identification. A recent paper reviewed the current development of organ-on-chip and their applications in drug discovery. Also, it is revealed the human-on-chip systems can recapitulate the complex dynamic process of drug absorption, distribution, metabolism and excretion to evaluate the efficacy and toxicity of drugs more reliably.
Fig.1 A schematic diagram of a microfluidic approach for establishing multiple organs-on-a-chip. (Ramadan, 2014)
Microfluidic devices offer a powerful platform for the development of vaccines. They have been used to develop and produce adjuvant formulations which are responsible for the enhancement of vaccine efficacy. Based on microfluidic nanoparticle generation systems, some new adjuvant types such as Saponins, ISCOMs, DOTAP nanoparticles plus D35, and DDAB:TDB are developed and optimized. Besides, microfluidic technologies are also applied for the high-throughput production of nanoparticles with special sizes and chemical properties. Vaccines encapsulated in nanoparticles can increase the stability of vaccines, improve delivery efficiency, control release profile. Interestingly, vaccine nanoparticles allow co-encapsulation with adjuvants and target molecules, enabling them to release on the target sites. In addition to these, microfluidic devices also offer a rapid, sensitive, and accurate analysis method for vaccine efficacy.
In the past decades, microfluidics technologies have been proposed as novel and versatile tools in the generation of nano- or micro-sized drug delivery systems. With the help of microfluidic devices, the drug delivery particles can be produced on a large scale and fabricated with various shapes, sizes, structures, and surface modifications. For example, the particle shell thickness can be precisely controlled by microfluidic devices, which allows the fine-tuning of the drug release profile of drug delivery particles for various drug release applications. Compared with the traditional bench method, the drug-loaded nanomaterials generated by microfluidic methods have better monodispersity, higher drug encapsulation efficiency, and longer blood circulation time.
Fig. 2 Microfluidic embryo harvesting and drug delivery chip. (Dong, 2018)
In-home high-level microfluidic technology team has many years of experience in the field of microfluidic-based drug and vaccine development. We provide customers with professional and high-quality drug and vaccine development services based on microfluidic technology. We promise to provide you with the best solutions to ensure your requirements are met. Our microfluidic-based services include but not limited to:
If you want to know more about our microfluidic-based vaccine development services, please directly contact us or send us an e-mail with specific requests.
For Research Use Only. Not For Clinical Use.